AUTHORS
Hamza Celik, PhD, Rebecca Buonpane, PhD2, Yazen Jmeian, PhD3, Lu Huo, PhD4, Fatoumata Jobe, PhD5, Gaurang Trivedi, PhD6, Brittney Wass, MS7, Angelo Brunelli Albertoni Laranjeira, PhD8, Emily Ren, PhD9, Matthew C. Stubbs, PhD10, J. Stewart New, PhD11, Mark Rupar, PhD12, Karthik Ramesh, PhD13, Angela Abdollahi, MS14, Shireen Shaikh15, Breann Barker, PhD16, Niketa Langalia, MS17, Li Zheng, PhD18, Edimara Reis, PhD19, Patrick Mayes, PhD20, Horacio Nastri, PhD21, Ricardo Macarron, PhD22
AFFILIATIONS
1 Incyte Corporation, Wilmington, Delaware, United States
2 Incyte Corporation, Wilmington, Delaware, United States
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Incyte Corporation, Wilmington, Delaware, United States
6 Incyte Corporation, Wilmington, Delaware, United States
7 Incyte Corporation, Wilmington, Delaware, United States
8 Incyte Corporation, Wilmington, Delaware, United States
9 Incyte Corporation, Wilmington, Delaware, United States
10 Incyte Corporation, Wilmington, Delaware, United States
11 Incyte Corporation, Wilmington, Delaware, United States
12 Incyte Corporation, Wilmington, Delaware, United States
13 Incyte Corporation, Wilmington, Delaware, United States
14 Incyte Corporation, Wilmington, Delaware, United States
15 Incyte Corporation, Wilmington, Delaware, United States
16 Incyte Corporation, Wilmington, Delaware, United States
17 Incyte Corporation, Wilmington, Delaware, United States
18 Incyte Corporation, Wilmington, Delaware, United States
19 Incyte Corporation, Wilmington, Delaware, United States
20 Incyte Corporation, Wilmington, Delaware, United States
21 Incyte Corporation, Wilmington, Delaware, United States
22 Incyte Corporation, Wilmington, Delaware, United States
ABSTRACT
Calreticulin (CALR) mutations occur in 25%–35% of myeloproliferative neoplasms, most commonly as a 52-bp deletion (Type 1) or 5-bp insertion (Type 2) in exon 9. Mutant CALR (mutCALR) traffics to the cell surface associated with thrombopoietin receptor, leading to malignant JAK-STAT signaling and exposing a neoantigen that can be targeted for selective therapeutic intervention.
INCA033989, a fully human, Fc-silenced IgG1 monoclonal antibody, represents the first generation of mutCALR-targeting therapeutics designed to selectively inhibit mutCALR-induced signaling while sparing normal hematopoiesis (Reis et al., Blood. 2024;144:2336-48). In ongoing phase 1 studies in patients with essential thrombocythemia (ET) and myelofibrosis (MF), INCA033989 has demonstrated rapid and durable hematologic and molecular responses, including reductions in mutCALR-positive hematopoietic stem/progenitor and megakaryocytic cells, improvements in bone marrow pathology, and biomarker evidence of disease modification with a favorable safety profile (Mascarenhas et al, EHA 2026 PS1983 and Harrison et al, EHA 2026 oral S216). These findings have supported initiation of the phase 3 EXCALIBUR-ET2 study in ET (NCT07623200), and phase 3 development in MF is planned.
Building on the clinical validation of INCA033989, we developed INCA041798, a next-generation mutCALR-targeting antibody, to enhance activity across major mutCALR variants while improving biophysical properties, stability, and substantially prolonging systemic exposure through Fc modifications.
INCA041798 bound both Type 1 and Type 2 mutCALR variants with high affinity (KD 53 pM and 260 pM, respectively). INCA041798 showed superior biological activity vs INCA033989, combining enhanced cell-surface binding with more potent inhibition of pSTAT5 signaling and cellular proliferation, including 4-fold and 70-fold increases in potency against Type 1 and Type 2 mutants, respectively. INCA041798 also maintained potent inhibitory activity across 8 additional noncanonical CALR exon 9 mutations, demonstrating broad coverage of clinically relevant mutCALR variants. Consistent with its Fc-engineering design and improved stability, INCA041798 demonstrated a ~15-fold improvement in half-life over INCA033989 in nonhuman primates and is projected to achieve a ~50-day half-life in humans, potentially supporting dosing every 4 weeks (q4w) or less frequent.
Enhanced activity was also confirmed in primary patient-derived CD34+ cells, where INCA041798 potently inhibited pSTAT5 signaling across independent samples harboring either Type 1 or Type 2 mutCALR variants. In functional studies using liquid culture assays, INCA041798 selectively suppressed spontaneous megakaryocyte differentiation from mutCALR CD34+ cells while sparing megakaryopoiesis from healthy donor CD34+ cells.
Disease-modifying activity was further evaluated in patient-derived xenograft models established from CD34+ cells harboring either Type 1 or Type 2 mutCALR variants. Following disease establishment, animals received INCA041798 treatment for 6 weeks. Treatment induced marked reductions in overall mutant-cell engraftment, accompanied by selective depletion of disease-driving hematopoietic populations, including CD33+ myeloid cells, CD41+ megakaryocytic cells, and CD34+ stem and progenitor cells. Notably, INCA041798 showed comparable efficacy in both Type 1 and Type 2 mutCALR-driven models, overcoming the reduced activity against Type 2 mutCALR previously observed with the clinical lead molecule, INCA033989.
Collectively, these data demonstrate that INCA041798 combines potent activity across different mutCALR variants with substantially prolonged systemic exposure, supporting its advancement as a differentiated next-generation mutCALR-targeting antibody. By delivering deep and sustained depletion of disease-driving cells in vivo, INCA041798 has the potential to provide more profound and durable disease modification for patients with mutCALR-driven malignancies while enabling convenient subcutaneous administration with q4w or longer dosing intervals. These findings support the clinical development of INCA041798, with a phase 1 study planned to initiate in early 2027.
DISCLOSURES
Hamza Celik, PhD: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment